SAN DIEGO–(BUSINESS WIRE)–Styx Biotechnologies, Inc., a San Diego-based biotechnology company developing next-generation antibody-drug conjugates (ADCs) for solid tumors, today announced a strategic agreement with ZoeNCure Therapeutics Pvt. Ltd. to accelerate selected Styx ADC programs toward first-in-human clinical studies. Under the agreement, Styx will receive an upfront payment and additional milestone-based payments tied to development progress. In exchange, ZoeNCure will provide develop
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
